Document is current
Any future updates will be listed below
-
Authors
Boisen, Matthew L.
Hartnett, Jessica N.
Shaffer, Jeffrey G.
Goba, Augustine
Momoh, Mambu
Sandi, John Demby
Fullah, Mohamed
Nelson, Diana K. S.
Bush, Duane J.
Rowland, Megan M.
Heinrich, Megan L. http://orcid.org/0000-0002-3079-6500
Koval, Anatoliy P.
Cross, Robert W.
Barnes, Kayla G.
Lachenauer, Anna E.
Lin, Aaron E. http://orcid.org/0000-0001-7400-4125
Nekoui, Mahan
Kotliar, Dylan
Winnicki, Sarah M.
Siddle, Katherine J.
Gbakie, Michael
Fonnie, Mbalu
Koroma, Veronica J.
Kanneh, Lansana
Kulakosky, Peter C.
Hastie, Kathryn M.
Wilson, Russell B.
Andersen, Kristian G.
Folarin, Onikepe O.
Happi, Christian T.
Sabeti, Pardis C.
Geisbert, Thomas W.
Saphire, Erica Ollmann http://orcid.org/0000-0002-1206-7451
Khan, S. Humarr
Grant, Donald S. http://orcid.org/0000-0002-4329-0795
Schieffelin, John S.
Branco, Luis M.
Garry, Robert F.
- License Information
-
More Information
Article History
Received: 16 February 2018
Accepted: 28 March 2018
First Online: 12 April 2018
Competing Interests
: The Viral Hemorrhagic Fever Consortium (available at: ExternalRef removed) is a partnership of academic and industry scientists who are developing diagnostic tests, therapeutic agents, and vaccines for Lassa fever, Ebola, and other severe diseases. Tulane University and its various academic and industry partners have filed US and foreign patent applications on behalf of the consortium for several of these technologies. Technical information may also be kept as trade secrets. If commercial products are developed, consortium members may receive royalties or profits. This does not alter our adherence to all policies of the NIH and <i>Scientific Reports</i> on sharing data and materials. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
